You are here:


Back to overview

PIMS-E is a pharmaceutical company based in Roden with its own development and production facilities. PIMS-E was founded as a result of a collaboration between the departments of Pharmaceutical Technology and Biopharmacy at the University of Groningen by Professor Dr. H. W. Frijlink. This unique collaboration provides PIMS-E with an experienced, enthusiastic and highly motivated team of researchers, pharmacists, pharmacy assistants, pharmaceutical experts, QA/RA professionals and product process developers.

PIMS-E used inhalation technology to develop an alternative to the Epipen™, Cyclops® (dry-powder inhalation): which administers adrenaline to people experiencing a life-threatening allergic reaction to bee or wasp stings or to medicines or food. The substance takes effect almost instantly through  powder inhalation, has a long shelf-life (it does not need to be stored in the fridge) and there is no further need for injections.

PIMS-E belongs to the fund:

Carduso Capital B.V.">

Carduso Capital participates in technology companies that are preferably based on the know-how represented in and originating from the Groningen science cluster in and around the University of Groningen (RUG) and the ...

View all the funds from the IFG

Cottonwood Technology Fund is an early stage fund that invests in deeptech/hard science startups with patented disruptiv...


CapitalT is a (pre-)seed fund that invests in companies which use AI to solve real world problems in climate tech, educa...